Stockreport

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies PRINCETON, N.J.--(BUSINESS WIRE)--Bristo [Read more]